1.	Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000454401, GERCOR-TAUROX, SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
2.	Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 to 74 Sponsor: Other Protocol IDs: 2009-03, NCT00868569
3.	Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2009-04, NCT00874406
4.	OPTIMOX1 in Chinese mCRC Patients Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: Oxali04882, NCT01023633
5.	Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: PROFUSE-2011, NCT01468623
6.	Correlation Between RECIST-conventional Imaging Techniques, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GEMCAD-1006, NCT01493713
7.	Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2012-03, NCT01564810
8.	A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT) Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML25753, NCT01588990
9.	A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225 AM1) (KMEC) Phase: Phase IV Type: Supportive care Status: Approved-not yet active Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 0869-225, MK-0869-225, NCT01636947
10.	Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000470411, FFCD-9902, SANOFI-FFCD-9902, LILLY-FFCD-9902, FFCD-FNCLCC-SFRO-9902, NCT00304135
11.	Radiation Therapy and Combination Chemotherapy as First-Line Therapy in Treating Patients With Esophageal Cancer That Cannot Be Removed by Surgery Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000595050, FRE-FNCLCC- ACCORD-17-0707, EU-20848, NCT00861094
12.	A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: FDRT-002, NCT01064999
13.	Phase II/III Randomized Study of the Influence of Micrometastases on Prognosis and Survival in Patients With Stage I or II Localized, Resectable Colon Cancer Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: JBZ-EnRoute+, EnRoute+, EUDRACT-2010-018612-32, EU-21016, NCT01097265
14.	Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-DLC-001, NCT01197560
15.	Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: BREC-AGC, NCT01206218
16.	5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FLOT4, NCT01216644
17.	Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 0291-1crgi09, NCT01348217
18.	Phase II/III Randomized Study of Neoadjuvant FOLFOX Therapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil Versus Chemoradiation Comprising Fluorouracil or Capecitabine and Radiation Therapy in Patients With Locally Advanced Rectal Cancer Undergoing Low-Anterior Resection With Total Mesorectal Excision Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N1048, N1048, NCT01515787
19.	Perioperative Chemotherapy for Potentially Resectable Gastric Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: TOTTG030103, NCT01516944
20.	Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EGC-0254/87/2011, UML-EGC-2011, NCT01523015
21.	Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 to 75 Sponsor: Other Protocol IDs: EORTC-1207, 2012-002317-18, NCT01646554
22.	Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors Phase: Phase III Type: Treatment Status: Active Age: Over 16 Sponsor: Other Protocol IDs: CDR0000416124, FRE-FNCLCC-GETUG-13/0206, EU-20502, NCT00104676
23.	Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Active Age: 75 and under Sponsor: Other Protocol IDs: FFCD 2000 – 05, CET 815, NCT00126256
24.	Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HEPATICA, NCT00394992
25.	Phase III Randomized Study of Adjuvant Chemotherapy Comprising Capecitabine and Oxaliplatin Versus Standard Follow-Up Care in Patients With Clear Margins After Complete Resection of Locally Advanced Rectal Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRUK-CHRONICLE, CRUK-BRD/05/132, EU-20679, ISRCTN59865116, CTA21106/0016/001, EUDRACT-2004-001484-21, NCT00427713